Tumor-Targeted Immunotherapy by Using Primary Adipose-Derived Stem Cells and an Antigen-Specific Protein Vaccine
Autor: | Win Ping Deng, Hsin Chung Cheng, Wen Cheng Lo, Navneet Kumar Dubey, Chun Chao Chang, Jui Hua Lu, Hong-Jian Wei, Joseph R. Wang, Bou Yue Peng |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2018 |
Předmět: |
0301 basic medicine
protein vaccine Cancer Research medicine.medical_treatment Biology lcsh:RC254-282 Article 03 medical and health sciences 0302 clinical medicine Immune system Antigen medicine antigen processing tumor microenvironment Tumor microenvironment Mesenchymal stem cell Immunotherapy lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens Endothelial stem cell 030104 developmental biology Oncology T cell responses 030220 oncology & carcinogenesis Cancer cell Cancer research adipose-derived stem cells Stem cell |
Zdroj: | Cancers, Vol 10, Iss 11, p 446 (2018) Cancers Volume 10 Issue 11 |
ISSN: | 2072-6694 |
Popis: | Cancer is a leading cause of mortality and a major public health problem worldwide. For biological therapy against cancer, we previously developed a unique immunotherapeutic platform by combining mesenchymal stem cells with an antigen-specific protein vaccine. However, this system possesses a few limitations, such as improperly immortalized mesenchymal stem cells (MSCs) along with transfected oncogenic antigens in them. To overcome the limitations of this platform for future clinical application, we freshly prepared primary adipose-derived stem cells (ADSCs) and modified the E7&rsquo antigen (E7&rsquo ) as a non-oncogenic protein. Either subcutaneously co-inoculated with cancer cells or systemically administered after tumor growth, ADSC labeled with enhanced green fluorescent protein (eGFP) and combined with modified E7&rsquo (ADSC-E7&rsquo eGFP) cells showed significant antitumor activity when combined with the protein vaccine in both colon and lung cancer in mice. Specifically, this combined therapy inhibited tumor through inducing cell apoptosis. The significantly reduced endothelial cell markers, CD31 and vascular endothelial growth factor (VEGF), indicated strongly inhibited tumor angiogenesis. The activated immune system was demonstrated through the response of CD4+ T and natural killer (NK) cells, and a notable antitumor activity might be contributed by CD8+ T cells. Conclusively, these evidences imply that this promising immunotherapeutic platform might be a potential candidate for the future clinical application against cancer. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |